WHO review in Lancet Microbe lists SynAct’s resomelagon candidate therapy
A WHO review published in Lancet Microbe names SynAct Pharma’s resomelagon as one of six dengue therapeutic candidates, citing evidence for further clinical development.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.